A Study of Stereotactic Radiosurgery (SRS) to Treat Pain in the Chest and/or Stomach Wall

Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Aug 2, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called stereotactic radiosurgery (SRS) to help relieve chronic pain in the chest and stomach area caused by certain diseases. The researchers want to find out if SRS is safe and effective for people who have been suffering from this type of pain for at least three months and have not found enough relief from standard pain medications. They will test different doses to identify the highest amount that causes only mild side effects.

To be eligible for this study, participants must be at least 18 years old and have ongoing pain that is linked to specific areas of the spine. They should also have a certain level of health, measured by a performance scale. However, there are some exclusions, such as having a life expectancy of less than six months or certain medical conditions. If you join the trial, you can expect to receive SRS treatment and be monitored for any side effects. This trial is currently recruiting participants, and it aims to improve pain management options for patients struggling with chronic thoracoabdominal wall pain.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients must have a documented history of chronic (≥ 3 months) thoracoabdominal wall pain (TAWP) attributable to ≤ 3 unilateral spinal levels as confirmed by diagnostic paravertebral nerve block or TENS (if results of the paravertebral nerve block are inconclusive) performed by an attending anesthesiologist specializing in pain management prior to study enrollment.
• • Patients must have TAWP that is inadequately relieved by a trial of conventional pharmacologic therapy (defined as NRS pain score ≥ 4/10 while on treatment with conventional pharmacologic therapy for analgesia) as determined by an attending physician specializing in pain management.
• • KPS ≥ 60%
• • Age ≥ 18 years old
• Exclusion Criteria:
• • Patients with a life expectancy of \< 6 months as predicted by the Adult Comorbidity Index (ACE-27, see Appendix 1)
• • Patients with active autoimmune connective tissue disease
• • Patients with bilateral TAWP
• • Patients with preexisting pneumothorax
• • Patients with preexisting excessive pleural effusion (extending \> 3 vertebral levels)
• • Systemic chemotherapy delivered or planned to be delivered within +/- 5 days of SRS
• • Unable to undergo a diagnostic paravertebral nerve block
• • Unable to undergo at least one of either a myelogram or spine MRI
• • Patients for whom external beam treatment plans to deliver the prescription SRS dose to the lesion of interest cannot be safely designed as specified by the Dose Constraint Guidelines in Appendix 2
• • Evaluation of any radiation doses previously delivered to spinal cord/cauda equina and other critical structures (bowel, esophagus, lungs, kidneys, rectum) will be taken into consideration
• • If radiation dose from SRS would exceed any normal tissue constraint as noted in Appendix 2, the patient will be ineligible
• * Abnormal complete blood count. Any of the following:
• • Platelet count \< 75 K/µL
• • Hgb level \< 9 g/dl
• • WBC \< 3.5 K/µl
• • Abnormal coagulation profile: INR \> 2.5 INR and/or APTT \> 80 seconds. Patients who are on anticoagulation medication that may not be safely held for the myelogram procedure (≥ 5 days for antiplatelet agents and warfarin; ≥ 24 hours for low-molecular weight heparin formulations) will be excluded.
• • Allergy to local anesthestics
• • Local infection at the site of injection of anesthetic
• • Severe spinal deformities with anatomic distortion (severe scoliosis/kyphoscoliosis)
• • Severe respiratory disease (i.e. oxygen dependent)